Vaccine

Cure© Hosts Power of X Summit to Drive Investment and Solutions in Untapped Trillion-Dollar Market Addressing Health of Women

Event's Impact Challenge to Award One Early-Stage Company Up to $100K for Innovative Women's Health Solutions NEW YORK, March 6,…

10 months ago

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

Two Presentations Highlight Data Demonstrating Hypericin Photodynamic Therapy Potential with a Preliminary Comparison to Current Therapy PRINCETON, N.J., March 6,…

10 months ago

Dyadic to Attend Multiple Industry Events in March

JUPITER, Fla., March 06, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI),…

10 months ago

Medical Refrigerators Market Size Set for Tremendous Growth, Projected to Reach US$ 6.49 Billion by 2028, Growing at 5.8% CAGR, Says The Insight Partners

NEW YORK, March 4, 2025 /PRNewswire/ -- According to a comprehensive report from The Insight Partners, "Medical Refrigerators Market Size and…

10 months ago

Ocugen Announces Positive Opinion of EMA’s Committee for Advanced Therapies for ATMP Classification for Novel Modifier Gene Therapy Candidate OCU410 for Geographic Atrophy and OCU410ST for Stargardt Disease

MALVERN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader…

10 months ago

GenBio AI Expands Global Leadership with Ziv Bar-Joseph as Co-Founder and Chief Scientific Officer

PARIS, Feb. 28, 2025 /PRNewswire/ -- GenBio AI, a leading company at the intersection of AI and biology, is excited…

10 months ago

AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza

Proposed study of Ampligen as a vaccine adjuvant to increase cross-reactivity to influenza strains Paul Goepfert, MD, Director for the…

10 months ago

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

Reported $781.4 million in full year 2024 revenues, representing 97% year-over-year growth SYFOVRE® (pegcetacoplan injection) full year 2024 net product…

10 months ago

Rapid Micro Biosystems Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Guidance

Reports record fourth quarter 2024 total revenue of $8.2 million, representing 30% growth compared to fourth quarter 2023; recurring revenue…

10 months ago

Nxera Pharma Enters Agreement with Holling to Commercialize Daridorexant in Taiwan

Daridorexant is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as…

10 months ago